Theriva Biologics Inc.
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase … Read more
Market Cap & Net Worth: Theriva Biologics Inc. (TOVX)
Theriva Biologics Inc. (NYSE MKT:TOVX) has a market capitalization of $6.46 Million ($6.46 Million) as of March 19, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #30612 globally and #10083 in its home market, demonstrating a 1.69% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Theriva Biologics Inc.'s stock price $0.18 by its total outstanding shares 35688349 (35.69 Million).
Theriva Biologics Inc. Market Cap History: 2015 to 2026
Theriva Biologics Inc.'s market capitalization history from 2015 to 2026. Data shows change from $715.11 Billion to $6.46 Million (-67.37% CAGR).
Theriva Biologics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Theriva Biologics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TOVX by Market Capitalization
Companies near Theriva Biologics Inc. in the global market cap rankings as of March 19, 2026.
Key companies related to Theriva Biologics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Theriva Biologics Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, Theriva Biologics Inc.'s market cap moved from $715.11 Billion to $ 6.46 Million, with a yearly change of -67.37%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $6.46 Million | -13.81% |
| 2025 | $7.49 Million | -88.00% |
| 2024 | $62.45 Million | -83.72% |
| 2023 | $383.65 Million | -4.44% |
| 2022 | $401.49 Million | -83.33% |
| 2021 | $2.41 Billion | -28.95% |
| 2020 | $3.39 Billion | -25.49% |
| 2019 | $4.55 Billion | -8.93% |
| 2018 | $5.00 Billion | -96.86% |
| 2017 | $159.26 Billion | -32.89% |
| 2016 | $237.33 Billion | -66.81% |
| 2015 | $715.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Theriva Biologics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.46 Million USD |
| MoneyControl | $6.46 Million USD |
| MarketWatch | $6.46 Million USD |
| marketcap.company | $6.46 Million USD |
| Reuters | $6.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.